
After 19 years of survivorship, one cancer survivor reflects on life's changing seasons, managing scan anxiety and finding support beyond treatment.
One prostate cancer combination is awaiting an FDA decision this year, and several late-stage trials could produce the next filings. Here's what to watch.
Prostate cancer had a strong summer at the FDA, with two approvals in June and July that moved targeted and radioligand therapy earlier in the disease. So what's next? One combination is under active FDA review with a decision expected before the end of the year, and several phase 3 trials are due to read out in the months ahead. Here is where things stand as of early September.






